E N H A N C I N G H E A LT H T H R O U G H C A N N A B I S S C I E N C E

Leveraging industry-leading greenhouse growing, cannabis and life sciences expertise to achieve highly competitive low cost, value added products for the large legal medical and future recreational cannabis market in Canada.

EMERALD HEALTH THERAPEUTICS INC.

TSX.V : EMHOTCQX : EMHTF

Price: $2.651Shares o/s: 93.1m2

Market Cap: $2471mCash: $22.8m2

3M Avg Vol: 580k3

52W H/L: $1.07-$2.73111/22/17 209/30/17 3TSX.V + OTCQX

Strategic investor, Emerald Health Sciences, owns 49%.

RECENT ADVANCES

10/02/17 Appoints pharmaceutical marketing and biotech executive, Chris Wagner, as CEO.

09/20/17 Scientific advisors publish research discovery of THCA cannabinoid’s neuroprotectivetreatment potential in British Journal of Pharmacology.

09/19/17 Expands supply via partnership with SupremePharmaceuticals.

06/14/17 Advisory board established to guide clinicalresearch pertaining to endocannabinoid system.

06/06/17 Formed 50/50 partnership with Village Farms. Existing 1.1M sf greenhouse can potentially produce 75,000 kg on cannabis. Option on two additional greenhouses with additional 225,000 kg potential.

1

Entered into transformational 50/50 partnership with Village Farms, one of North America’s largest vertically integrated greenhouse vegetable growers, forming Pure Sunfarms Corp. to convert 1.1 million sq ft greenhouse for large-scale cannabis cultivation

Building a wholly owned cultivation and extraction facility on 32 acre property in metro Vancouver - initially adding 100,000 sf, with potential for up to 1 million sf of cultivation area

$22.8 million in treasury

Unique product development through proprietary characterized strains

Downstream focus on high margin products through extraction and capsulation, supported by change to substantial input capacity from Pure Sunfarms greenhouse and our own metro Vancouver expansion

Recent publishing of scientific advisors’ research on neuroprotective potential of THCA is prelude to imminent initiation of first clinical study

COMPANY HIGHLIGHTS

STRATEGIC STEPS TO CREATE PROMINENT INDUSTRY POSITIONING

One of the industry’s most qualified management teams in life sciences, cannabis cultivation & large scale agri-business.. Management & board members have raised ~$500m for development-stage companies and run clinical trials with aggregate budgets exceeding $1B. Executive Chairman is former CEO of Inovio; CEO has 20+ years in life sciences; CFO has 20+ years in finance and accounting.

Partnership with Village Farms, called Pure Sunfarms, adds decades of large scale greenhouse growing experience and strategically positions Emerald for rapid production capacity expansion in anticipation of the future adult-use market. Reduces execution risk for Emerald to implement and operate large-scale growing and provides significant quantity of quality inputs for extraction and downstream product development. Emerald has preferred access to Sunfarms’ production.

Focus on producing high quality cannabinoid products with well-characterized, consistent attributes using cultivation and GMP compliant extraction and processing to meet pharmaceutical standards.

Opportunity to deliver proprietary medical quality cannabinoid products with low or no psychoactive effects will open the door to new consumers seeking alternative, non-addictive approaches to insomnia, pain, and other conditions with unmet needs. Future initiatives include generating clinical evidence of utility with unique formulated products.

LOOKING AHEAD

2

on

site.

BOARD OF DIRECTORS

Avtar Dhillon, MD - Chairman and former CEO of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). Board member of several life sciences companies.

Bob Rai, BSc - Chairman and CEO of Canadian Pacific Global Pharmaceuticals. Director of Vanc Pharmaceutica Inc. (TSX:NPH).

Chris Wagner, BSc 25 years experience in pharmaceutical product development and marketing expertise.

Jim Heppell, LLP - Previous President and Director of BC Advantage Funds. Founding CEO and Director of Sophiris Bio Inc. (NASDAQ:SPHS).

Punit Dhillon, BA - President & CEO of Oncosec Medical Inc. (NASDAQ: ONCS).

MANAGEMENT

Chris Wagner, BSc CEO with over 25 years experience in pharmaceutical product development and marketing expertise.

Bin Huang, PhD, MBA. - President of Emerald Health Botanicals with over 20 years experience in the life sciences sector, including over 10 years as CEO of public companies.

Robert Hill, CA/CPA. - CFO with over 20 years experience in accounting and finance. Former CFO of Minkabu Inc.

Traviss Graham - VP Production with 15 years experience in cannabis production and processing, as well as product development.

Frey Garabagi, PhD (Guelph). - VP R&D and QAP with over 10 years R&D experience in plant molecular genetics and medical technologies

The world’s largest legal marketfor recreational cannabis

Canada’s government has proposedlegislation to legalize and regulaterecreational cannabis by July 1, 2018. Emerald is expandingcapacity to meet the demand andgrowth of the anticipated legaladult-use market.

Legalization would make Canadathe world’s largest legal market for recreational cannabis, whichDeloitte estimates may exceed $22.6B (including ancillary products/services).

Based on ongoing development of unique products containing desired ratios of cannabinoids

The company is developing newproducts based on its ongoingresearch to characterize cannabisstrains and their attributes, inparticular strains with high CBDlevels with the potential to serveunmet medical needs.

For more information, contact:

INVEST@EMERALDHEALTH.CA TSX.V : EMH | OTCQX : EMHTF

EMERALDHEALTH.CA

BOARD & MANAGEMENT

PEERS MARKET CAP2

M A R K E T C A P 1$247M

2 0 2 0 C A PA C I T Y

~$1.4B AV E R A G E

M A R K E T C A P / KG$5,145 ~$19,900AV E R A G E

PEER COMPARATIVE VALUE

Emerald production +50% of partnership production

48,000 kg

PURE SUNFARMS PARTNERSHIP: UNMATCHED SCALE & LOW OPERATING COST POTENTIAL

1.1m s.f. initial greenhouse facility represents one of Canada’s largest single cannabis growing facilities, with production potential of ~ 75,000 kg Option on two additional greenhouses with 3.7m s.f. provides unmatched production potential

PRODUCTION SCALABILITY

Decades of large-scale greenhouse growing experience plus extensive cannabis growing expertise in optimally configured facility

VERY LOW COST GROWING

1 – 11/22/172 WEED, APH, ACB, MJN, LEAF, TRST, CMED

~78,000 kgAV E R A G E